181 related articles for article (PubMed ID: 21498390)
1. Skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus: role of tigecycline.
Curcio D
Clin Infect Dis; 2011 Jun; 52(12):1468-9. PubMed ID: 21498390
[No Abstract] [Full Text] [Related]
2. Treatment of skin and soft tissue infections due to community-associated methicillin-resistant Staphylococcus aureus in Europe: the role of trimethoprim-sulfamethoxazole0010.
De Angelis G; Cipriani M; Cauda R; Tacconelli E
Clin Infect Dis; 2011 Jun; 52(12):1471-2; author reply 1472. PubMed ID: 21628490
[No Abstract] [Full Text] [Related]
3. Methicillin-resistant Staphylococcus aureus infection epidemiology and clinical response from tigecycline soft tissue infection trials.
Puzniak LA; Quintana A; Wible M; Babinchak T; McGovern PC
Diagn Microbiol Infect Dis; 2014 Jun; 79(2):261-5. PubMed ID: 24725736
[TBL] [Abstract][Full Text] [Related]
4. Oral antimicrobial options for the treatment of skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in the UK.
Enoch DA; Karas JA; Aliyu SH
Int J Antimicrob Agents; 2009 Jun; 33(6):497-502. PubMed ID: 19101123
[TBL] [Abstract][Full Text] [Related]
5. Drugs for MRSA skin and soft-tissue infections.
Med Lett Drugs Ther; 2014 May; 56(1442):39-40. PubMed ID: 24818839
[No Abstract] [Full Text] [Related]
6. Treatment options for skin and soft tissue infections caused by meticillin-resistant Staphylococcus aureus:oralvs.parenteral; home vs. hospital.
Esposito S; Leone S; Petta E; Noviello S; Ianniello F
Int J Antimicrob Agents; 2009 Jul; 34 Suppl 1():S30-5. PubMed ID: 19560673
[TBL] [Abstract][Full Text] [Related]
7. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Whitman TJ
Dis Mon; 2008 Dec; 54(12):780-6. PubMed ID: 18996280
[No Abstract] [Full Text] [Related]
8. Minocycline for the treatment of community-acquired Staphylococcus aureus infections.
Gelfand MS; Mazumder SA; Cleveland KO
Int J Antimicrob Agents; 2014 Apr; 43(4):385-6. PubMed ID: 24613609
[No Abstract] [Full Text] [Related]
9. Minocycline is a reliable and effective oral option to treat meticillin-resistant Staphylococcus aureus skin and soft-tissue infections, including doxycycline treatment failures.
Cunha BA
Int J Antimicrob Agents; 2014 Apr; 43(4):386-7. PubMed ID: 24559866
[No Abstract] [Full Text] [Related]
10. Diabetic foot infection caused by community-associated methicillin-resistant Staphylococcus aureus (USA300).
Echániz-Aviles G; Velazquez-Meza ME; Vazquez-Larios Mdel R; Soto-Noguerón A; Hernández-Dueñas AM
J Diabetes; 2015 Nov; 7(6):891-2. PubMed ID: 26119276
[No Abstract] [Full Text] [Related]
11. Comparative efficacy of tigecycline VERSUS vancomycin in an experimental model of soft tissue infection by methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin.
Antonopoulou A; Tsaganos T; Tzepi IM; Giamarellou H; Giamarellos-Bourboulis EJ
J Chemother; 2015 Feb; 27(2):80-6. PubMed ID: 24548093
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for complicated skin and skin-structure infections.
Mendoza N; Tyring SK
Expert Opin Emerg Drugs; 2010 Sep; 15(3):509-20. PubMed ID: 20557269
[TBL] [Abstract][Full Text] [Related]
13. What is the place of linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia and complicated skin and soft tissue infections in Europe?
Dumitrescu O; Lina G
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():1-2. PubMed ID: 24580737
[No Abstract] [Full Text] [Related]
14. Minocycline, often forgotten but preferred to trimethoprim-sulfamethoxazole or doxycycline for the treatment of community-acquired meticillin-resistant Staphylococcus aureus skin and soft-tissue infections.
Cunha BA
Int J Antimicrob Agents; 2013 Dec; 42(6):497-9. PubMed ID: 24126085
[TBL] [Abstract][Full Text] [Related]
15. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Hyun DY; Mason EO; Forbes A; Kaplan SL
Pediatr Infect Dis J; 2009 Jan; 28(1):57-9. PubMed ID: 19057459
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs).
Cunha BA
Eur J Clin Microbiol Infect Dis; 2014 Oct; 33(10):1869-71. PubMed ID: 24838676
[No Abstract] [Full Text] [Related]
17. A prospective observational cohort study in primary care practices to identify factors associated with treatment failure in Staphylococcus aureus skin and soft tissue infections.
Lee GC; Hall RG; Boyd NK; Dallas SD; Du LC; Treviño LB; Treviño SB; Retzloff C; Lawson KA; Wilson J; Olsen RJ; Wang Y; Frei CR
Ann Clin Microbiol Antimicrob; 2016 Nov; 15(1):58. PubMed ID: 27876059
[TBL] [Abstract][Full Text] [Related]
18. Changes in prescriptive practices in skin and soft tissue infections associated with the increased occurrence of community acquired methicillin resistant Staphylococcus aureus.
Meddles-Torres C; Hu S; Jurgens C
J Infect Public Health; 2013 Dec; 6(6):423-30. PubMed ID: 23999333
[TBL] [Abstract][Full Text] [Related]
19. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.
Quist SR; Fierlbeck G; Seaton RA; Loeffler J; Chaves RL
Int J Antimicrob Agents; 2012 Jan; 39(1):90-1. PubMed ID: 21982144
[No Abstract] [Full Text] [Related]
20. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
